EverHint Lens - Centessa Pharmaceuticals plc ($CNTA) - Yahoo Finance Top Gainer Stock (+45%) Analysis - March 31, 2026

Analysis Date: 2026-03-31
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

Executive Summary

Centessa Pharmaceuticals plc is currently trading at $39.96 (🟢 +44.89% today) with a market capitalization of $5.37B.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.

Price & Valuation

Current Price: $39.96 (at 12:01 PM ET)
Current Volume: 25.8M
Day Range: $39.81 - $40.25
52-Week Range: $9.60 - $40.25
P/E Ratio: -22.08

DCF Valuation: Overvalued

• Intrinsic Value (Unlevered DCF): $2.62
• Current Price: $39.96
• Discount/Premium: -93.4%

Levered DCF: $2.32 (-94.2%)

DCF analysis suggests the stock may be trading at a 93.4% premium to its intrinsic value.

DCF values calculated as of 2026-03-31. Underlying assumptions are not disclosed by the data provider. Levered vs unlevered can diverge materially for highly levered companies.

Market Context

Major Indices:

• S&P 500: $6429.37 (🟢 +1.35%)
• NASDAQ Composite: $21169.24 (🟢 +1.80%)
• Dow Jones Industrial Average: $45677.85 (🟢 +1.02%)

Peer Comparison

Peer comparison (11 companies):

• CNTA - Centessa Pharmaceuticals plc ($39.96, +44.9%, $5.37B) ← Current
• CGON - CG Oncology, Inc. Common stock ($67.34, +5.3%, $5.69B)
• CELC - Celcuity Inc. ($111.61, +3.1%, $5.39B)
• APGE - Apogee Therapeutics, Inc. ($84.16, +6.9%, $4.71B)
• XENE - Xenon Pharmaceuticals Inc. ($57.87, +4.2%, $4.57B)
• LEGN - Legend Biotech Corporation ($17.97, +3.8%, $3.32B)
• DYN - Dyne Therapeutics, Inc. ($17.55, +2.7%, $2.90B)
• AAPG - Ascentage Pharma Group International ($23.64, +2.1%, $2.20B)
• ZLAB - Zai Lab Limited ($18.36, +2.8%, $2.03B)
• RARE - Ultragenyx Pharmaceutical Inc. ($20.61, +6.8%, $1.99B)
• SLNO - Soleno Therapeutics, Inc. ($33.96, +11.6%, $1.82B)

Financial Performance

Latest Quarter (2025-09-30):

• Revenue: $0.00M
• Net Income: $-54.89M
• EPS: $-0.41

Earnings Calendar

Next Earnings Report: 2026-05-18 (Before Market Open)

• EPS Estimate: $-0.37

Most Recent Report: 2026-03-31

Historical Data: 25 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $38.60 (-3.4% upside)
• Range: $35.00 - $42.00
• Median: $38.00

Next Quarter Estimates (2027-12-30):

• EPS: $-0.43

Analyst Consensus

Overall Rating: Buy

Rating Distribution (51 total ratings):

• 🟢 Buy/Outperform: 36 (70.6%)
• ⚪ Hold/Neutral: 9 (17.6%)
• 🔴 Sell/Underperform: 4 (7.8%)

Recent Analyst Actions:

• Wolfe Research (2026-02-23): Initiate Outperform
• Stephens (2025-10-28): Initiate Overweight
• Wells Fargo (2025-09-02): Initiate Overweight
• Chardan Capital (2025-05-08): Initiate Buy
• Oppenheimer (2025-05-08): Initiate Outperform

Consensus based on 51 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 3 trading signal(s) in the last 60 days:

• 2026-03-25: Momentum Swing - pullback @ $28.22
• 2026-02-19: Sma20 Sma50 - SMA20_x_SMA50_Buy @ $24.96
• 2026-02-18: Ema10 Ema30 - EMA10_x_EMA30_Buy @ $25.04

Insider Activity

Recent Transactions (Last 10):

• Buys: 4
• Sells: 6

Notable Transactions:

• 2026-03-26: Anderson Karen M. - Buy (Option Exercise, 41,076 shares @ $8.01)
• 2026-03-26: Anderson Karen M. - Sell (Option Exercise, 41,076 shares @ $8.01)
• 2026-03-26: Anderson Karen M. - Sell (Sale, 41,076 shares @ $30.12)

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

Centessa Pharmaceuticals (CNTA) sentiment is overwhelmingly positive, driven by Eli Lilly's $6.3B-$7.8B acquisition announcement to bolster its neuroscience portfolio with Centessa's orexin agonists for sleep disorders. Analyst consensus ratings of 'Buy' or 'Moderate Buy,' pipeline milestones, and stock surges further support bullish views. Isolated insider sales and a fair price investigation are minor amid the dominant deal news.

Key Themes:

• Eli Lilly Acquisition
• Analyst Buy Ratings
• Pipeline Progress

Sentiment: Positive (95% confidence)

Recent News

5 most recent articles covering CNTA:

• Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio (proactiveinvestors.com, 2026-03-31) — Read more
• Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs (cnbc.com, 2026-03-31) — Read more
• Why Eli Lilly Is Buying Centessa for $7.8 Billion (youtube.com, 2026-03-31) — Read more
• CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders (businesswire.com, 2026-03-31) — Read more
• Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion (wsj.com, 2026-03-31) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-03-31 09:01:50 AM PDT

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.